Neurovan-25 Capsule: Each capsule contains Pregabalin BP 25 mg.
Neurovan-50 Capsule: Each capsule contains Pregabalin BP 50 mg.
Neurovan-75 Capsule: Each capsule contains Pregabalin BP 75 mg.
Pregabalin is an analog of the neurotransmitter gamma-aminobutyric acid (GABA). It has analgesic and anticonvulsant activity. Pregabalin binds to an auxiliary subunit ( 2 protein) of voltage-gated calcium channels in the central nervous system and reduces calcium influx into the nerve terminals. It decreases the release of neurotransmitters such as glutamate, noradrenaline and Substance P. It also increases neural GABA levels by producing a dose dependent increase in Glutamic Acid Decarboxylase (GAD) activity. GAD is the enzyme that converts the excitatory glutamate into inhibitory GABA in a single step. Binding of Pregabalin to the 2 site is required for analgesic and anticonvulsant activity.
Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans, it does not inhibit drug metabolism.
Pregabalin is contraindicated in patients with known hypersensitivity to Pregabalin.
Dry mouth, constipation, nausea, vomiting, flatulence, dizziness, drowsiness etc. may occur. Drug interactions: Since Pregabalin is predomitantly excreted unchanged in the urine, undergoes negligible metabolism in humans, it does not inhibit drug metabolism.
Use in pregnancy: There are no adequate and well-controlled studies on pregnant women. Nepafenac should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Use in lactation: It is not known whether this drug is excreted in human milk. So, caution should be exercised when Nepafenac ophthalmic suspension is administered to a nursing mother.
Use in children: Safety and effectiveness in pediatric patients below 10 years of age have not been established.
Use in elderly patients: No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Patients with hereditary problems of galactose metabolism should not take Pregabalin. In some diabetic patients who gain weight on Pregabalin treatment may need to adjust hypoglycemic medications. Pregabalin should be discontinued immediately if symptoms of angioedema such as facial perioral, or upper airway swelling occur. Antiepileptic drugs (AED), including Pregabalin, increase the risk of suicidal thoughts or behaviour in patients taking these drugs for any indication. Pregabalin should be discontinued if myopathy is diagnosed or suspected or if markedly elevated creatinine kinase levels occur.
Store below 30 C, keep in dry place and protect from light. Keep out of the reach of the children.